We recently addressed this topic too by evaluating the frequency of an extended panel of cancer-relevant mutations that could have possibly affected the initial response to erlotinib in a consecutive series of EGFRM+/ALK-negative/ROS1-negative advanced NSCLCs [51]. This evidence concerns the gene ALK and cancer.